कृपया अन्य खोज का प्रयास करें
चिन्ह | एक्सचेंज | करेंसी | ||
---|---|---|---|---|
ONC | टोरंटो | CAD | रियल टाइम | |
ONCY | NASDAQ | USD | रियल टाइम | |
ONC | CBOE कनाडा | CAD | रियल टाइम |
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Matthew C. Coffey | - | 1999 | President, CEO & Director |
Wayne F. Pisano | 68 | 2013 | Independent Chairman of the Board |
Deborah M. Brown | - | 2017 | Independent Director |
Angela Frances Holtham | 72 | 2014 | Independent Director |
Jean-Pierre Bizzari | 69 | - | Member of Scientific Advisory Board |
Bernd Robert Seizinger | 68 | 2015 | Independent Director |
Aleix Prat | - | - | Member of Scientific Advisory Board |
Padmanee Sharma | - | - | Member of Scientific Advisory Board |
Martine Piccart | - | 2017 | Member of Scientific Advisory Board |
James T. Parsons | 59 | 2022 | Independent Director |
Richard Vile | - | 2020 | Member of Scientific Advisory Board |
Jonathan M. N. Rigby | 56 | 2022 | Independent Director |
Patricia S. Andrews | 65 | 2024 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है